CelLBxHealth has secured a collaboration with AdventHealth to use its Parsortix platform in two US clinical cancer studies, ACTION and SUNRISE. These trials will analyze circulating tumor cells (CTCs) from blood samples of patients with colon, gastrointestinal, and lung cancers to monitor tumor response to treatment non-invasively. The collaboration aims to improve cancer care accessibility by enabling advanced monitoring through simple blood draws, potentially reducing the need for invasive biopsies. AdventHealth's extensive US network offers CelLBxHealth a strong platform to validate and expand Parsortix's clinical use.
During week 20 of 2026 (May 11-15), Sampo Oyj repurchased a total of 1,730,961 of its A-shares across multiple marketplaces at an average price of about €8.92 per share. This buyback is part of a €350 million share repurchase program authorized by th...
Anthony Scaramucci criticized the US decision to grant China permanent trade relations and WTO membership, saying it allowed China to protect its economy while exporting freely to the US. He argued that China used this advantage to take US technology...
Anglo American has agreed to sell its Australian coking coal business for up to $3.875 billion in cash to UK-based Dhilmar Ltd. The deal includes an upfront payment of $2.3 billion and an earnout of up to $1.575 billion linked to coal prices over fiv...
Netflix's ad-supported plan now reaches over 250 million global monthly active viewers, marking a major scale milestone. The company aims to convince advertisers that these viewers are valuable enough to pay premium prices, especially by leveraging l...
The Avantis U.S. Small Cap Value ETF (AVUV) provides broad exposure to U.S. small-cap value stocks with over 700 holdings and a moderate expense ratio of about 0.25%. Small-cap value stocks currently trade at lower valuation multiples compared to lar...
